Abbott has received approval from Health Canada for the Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease.
Abbott Park, Ill.-based company said it will launch Xience V in Canada immediately.
Xience V is built upon Abbott's bare-metal stent, the Multi-Link Vision coronary stent system. Abbott said its Vision platform is designed to facilitate ease of delivery to maneuver the stent and treat the diseased portion of the artery. The Xience V drug-coated stent will be available on both over-the-wire and rapid exchange delivery systems.